Biodegradable synthetic polymers: raw-materials and production methods of microparticles for drug delivery and controlled release

Micropartículas produzidas a partir de polímeros sintéticos têm sido amplamente utilizadas na área farmacêutica para encapsulação de princípios ativos. Essas micropartículas apresentam as vantagens de proteção do princípio ativo, mucoadesão e gastrorresistência, melhor biodisponibilidade e maior adesão do paciente ao tratamento. Além disso, utiliza menores quantidade de princípio ativo para obtenção do efeito terapêutico proporcionando diminuição dos efeitos adversos locais, sistêmicos e menor toxidade. Os polímeros sintéticos empregados na produção das micropartículas são classificados biodegradáveis ou não biodegradáveis, sendo os biodegradáveis mais utilizados por não necessitam ser removidos cirurgicamente após o término de sua ação. A produção das micropartículas poliméricas sintéticas para encapsulação tanto de ativos hidrofílicos quanto hidrofóbicos pode ser emulsificação por extração e/ou evaporação do solvente; coacervação; métodos mecânicos e estão revisados neste artigo evidenciando as vantagens, desvantagens e viabilidade de cada metodologia. A escolha da metodologia e do polímero sintético a serem empregados na produção desse sistema dependem da aplicação terapêutica requerida, bem como a simplicidade, reprodutibilidade e factibilidade do aumento de escala da produção2144286292COORDENAÇÃO DE APERFEIÇOAMENTO DE PESSOAL DE NÍVEL SUPERIOR – CAPESFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO – FAPESPsem informaçãoMicroparticles produced from synthetic polymers have been widely used in the pharmaceutical field for encapsulation of drugs. These microparticles show several advantages such as drug protection, mucoadhesion, gastro-resistance, improved bioavailability and increased patient's compliance. In addition, it is possible to use lower amount of drug to achieve therapeutic efficiency with reduced local/ systemic adverse side effects and low toxicity. Synthetic polymers used for the production of microparticles are classified as biodegradable or non-biodegradable, being the former more popular since these do not need to be removed after drug release. Production of polymeric microparticles can be used for encapsulation of hydrophilic and hydrophobic drugs, by emulsification following solvent extraction/ evaporation, coacervation, methods that are revised in this paper, including advantages, disadvantages and viability of each methodology. Selection of methodology and synthetic polymer depends of the therapeutic purpose, as well as simplicity, reproducibility and possibility to scale up

Isolation and characterization of two plant growth-promoting bacteria from the rhizoplane of a legume (Lupinus albescens) in sandy soil

Duas linhagens bacterianas que apresentaram amplificação de parte do gene nifH, RP1p e RP2p, pertencentes aos gêneros Enterobacter e Serratia, foram isoladas do rizoplano de Lupinus albescens. Essas bactérias são Gram-negativas, com formato de bastonete, móveis, anaeróbias facultativas e apresentam multiplicação rápida, com colônias alcançando diâmetros de 3–4 mm em 24 h de incubação a 28 ºC. RP1p e RP2p também foram capazes de multiplicação em temperaturas elevadas, como 40 ºC, na presença de alta concentração de NaCl (2–3 % v/v) e em valores de pH que variaram de 4 a 10. A linhagem RP1p foi capaz de utilizar 10 das 14 fontes de carbono avaliadas, enquanto a linhagem RP2p utilizou nove. Os isolados produziram sideróforos e compostos indólicos, mas foram incapazes de solubilizar fosfatos. A inoculação de L. albescens com as linhagens RP1p e RP2p resultou em aumento significativo do peso das plantas secas, o que demonstra que essas bactérias apresentam propriedades que favorecem o crescimento vegetal.Two bacterial strains that amplified part of the nifH gene, RP1p and RP2p, belonging to the genus Enterobacter and Serratia, were isolated from the rhizoplane of Lupinus albescens. These bacteria are Gram-negative, rod-shaped, motile, facultative anaerobic, and fast-growing; the colonies reach diameters of 3–4 mm within 24 h of incubation at 28 °C. The bacteria were also able to grow at temperatures as high as 40 °C, in the presence of high (2–3 % w/v) NaCl concentrations and pH 4 -10. Strain RP1p was able to utilize 10 of 14 C sources, while RP2p utilized nine. The isolates produced siderophores and indolic compounds, but none of them was able to solubilize phosphate. Inoculation of L. albescens with RP1p and RP2p strains resulted in a significant increase in plant dry matter, indicating the plant-growth-promoting abilities of these bacteria

Lycopene: total-scale literature landscape analysis of a valuable nutraceutical with numerous potential applications in the promotion of human and animal health

Lycopene intake from tomatoes and other food sources has multiple potential health benefits. This report aimed to evaluate the current research literature on lycopene concerning human and animal health. The electronic Web of Science Core Collection database was searched with (lycopene*) AND (health* OR illness* OR disease* OR medic* OR pharma* OR drug* OR therap*). The resulted 3972 papers were analyzed with the aid of bibliometric software. Besides the United States, the lycopene papers received global contributions, particularly from China, Italy, India, and Spain. Examples of frequently mentioned chemicals/chemical classes were carotenoid, beta carotene, alpha carotene, beta cryptoxanthin, and alpha tocopherol. Examples of frequently mentioned medical conditions were prostate cancer, cardiovascular disease, and obesity. Published scientific articles reveal the diverse potential of lycopene in prompting human and animal health, and the knowledge on the bioactivities of this phytochemical is expected to further grow in the future

Crescimento de eucalipto sob efeito de desfolhamento artificial

O objetivo deste trabalho foi avaliar os efeitos do desfolhamento total, realizado após o plantio e ao longo do primeiro ano de cultivo, sobre o crescimento de Eucalyptus grandis, desde a implantação até ao corte do povoamento. Foram avaliados cinco tratamentos: sem desfolhamento; um desfolhamento aos 56 dias após o plantio (DAP); dois desfolhamentos, aos 56 e 143 DAP; dois desfolhamentos, aos 56 e 267 DAP; e três desfolhamentos, aos 56, 143 e 278 DAP. Foram mensurados os diâmetros do tronco a 1,3 m e a altura total de 60 árvores por tratamento, em oito avaliações, do 21º ao 92º mês de cultivo. O crescimento médio em cada tratamento foi descrito por modelos de regressão não lineares e comparados por testes de identidade para comparar as tendências entre a testemunha e os demais tratamentos. O desfolhamento causou reduções significativas nas taxas de crescimento em diâmetro e altura das plantas, e diminuição expressiva no faturamento ao final da rotação, mesmo quando realizado uma única vez, no início do plantio. Maiores danos, no entanto, foram verificados após consecutivos desfolhamentos ao longo do primeiro ano de cultivo. A manutenção de áreas que tenham sofrido desfolhamento total na fase inicial de plantio pode tornar-se uma medida economicamente inviável.The objective of this work was to evaluate the effects of total defoliation at planting initial stages, and along the first year of cultivation, on Eucalyptus grandis growth, from planting to plantation cut. Five treatments were tested: without defoliation; one defoliation, at 56th day after planting (DAP); two defoliations, at 56th and 143th DAP; two defoliations, at 56th and 267th DAP; and three defoliations, at 56th, 143th and 278th DAP. Trunk diameter at 1.30-m height and the total height of 60 trees were measured from the 21st to the 92th cultivation months. The average growth of each treatment was described by nonlinear models and compared by identity tests in order to estimate the tendencies between control and the other treatments in each variable. Defoliation significantly reduces diameter of the trunk and height growth rates, and expressively decreases the income at the plantation cut. However, greater losses were verified after consecutive defoliation, along the first cultivation year. Maintaining areas that suffered severe defoliations at initial planting stages can become economically unfeasible

Spread of a SARS-CoV-2 variant through Europe in the summer of 2020.

Following its emergence in late 2019, the spread of SARS-CoV-21,2 has been tracked by phylogenetic analysis of viral genome sequences in unprecedented detail3–5. Although the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced. However, travel within Europe resumed in the summer of 2020. Here we report on a SARS-CoV-2 variant, 20E (EU1), that was identified in Spain in early summer 2020 and subsequently spread across Europe. We find no evidence that this variant has increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant’s success. Despite travel restrictions, we estimate that 20E (EU1) was introduced hundreds of times to European countries by summertime travellers, which is likely to have undermined local efforts to minimize infection with SARS-CoV-2. Our results illustrate how a variant can rapidly become dominant even in the absence of a substantial transmission advantage in favourable epidemiological settings. Genomic surveillance is critical for understanding how travel can affect transmission of SARS-CoV-2, and thus for informing future containment strategies as travel resumes. © 2021, The Author(s), under exclusive licence to Springer Nature Limited

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time, and attempts to address it require a clear understanding of how ecological communities respond to environmental change across time and space. While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes, vast areas of the tropics remain understudied. In the American tropics, Amazonia stands out as the world's most diverse rainforest and the primary source of Neotropical biodiversity, but it remains among the least known forests in America and is often underrepresented in biodiversity databases. To worsen this situation, human-induced modifications may eliminate pieces of the Amazon's biodiversity puzzle before we can use them to understand how ecological communities are responding. To increase generalization and applicability of biodiversity knowledge, it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple organism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region's vulnerability to environmental change. 15%–18% of the most neglected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lost

Preparation Of Polymeric Nanoparticles By Polymerization Of Monomers - Part I [preparação De Nanopartículas Poliméricas A Partir Da Polimerização De Monômeros - Parte I]

Polymeric nanoparticles obtained from synthetic polymers such as copolymers of methacrylic acid, acrylic esters or metacrylics, have been widely used in pharmaceuticals for encapsulation of drugs. These nanoparticles have the advantages of drug protection, controlled release, improved bioavailability and lower toxicity, resulting in greater comfort to patients and compliance to the treatment. The production of nanoparticles (nanospheres and nanocapsules) by polymerization of monomers is reviewed and discussed in this article, highlighting the technological parameters that affect the physicochemical characteristics of nanoparticles, e.g. drug solubility, phase volume, pH of polymerization, molecular weight and monomer concentration, and the nature and concentration of the surfactant.22196100Nicolas, J., Couvreur, P., (2009) Rev. Nanomed. Nanobiotechnol., 1, p. 111. , http://dx.doi.org/10.1002/wnan.15, PMidp20049783Severino, P., Santana, M.H., Pinho, S.C., Souto, E.B., (2011) Polímeros, , in pressAraújo, J., Veja, V., Lopes, C.M., Egea, M.A., García, M.L., Souto, E.B., (2009) Colloid Surf B Biointerfaces, 72, p. 48Schaffazick, S.R., Stanisçuaski, S.G., Freitas, L.L., Pohlmann, A.R., (2003) Quím Nova, 26, p. 726. , http://dx.doi.org/10.1590/S0100-40422003000500017Liu, H., Chen, J., (2009) J. Pharm. Sci. Technol., 63, p. 207Garg, N.K., Mangal, S., Khambete, H., Sharma, P.K., Tyagi, R.K., (2010) Recent Pat. Drug Deliv. Formul., 4, p. 114Liu, D., Wang, L., Liu, Z., Zhang, C., Zhang, N., (2010) J. Biomed. Nanotechnol., 6, p. 675. , http://dx.doi.org/10.1166/jbn.2010.1160Chellampillai, B., Pawar, A.P., (2011) Eur. J. Drug Metab. Pharmacokinet., 35, p. 123. , http://dx.doi.org/10.1007/s13318-010-0016-7Zhang, W., Gao, J., Zhu, Q., Zhang, M., Ding, X., Wang, X., Hou, X., Gao, S., (2010) Int J. Pharm., 402, p. 205. , http://dx.doi.org/10.1016/j.ijpharm.2010.09.037Anancharungsuk, W., Polpanich, D., Jangpatarapongsa, K., Tangboriboonrat, P., (2010) Colloids Surf B Biointerfaces, 78, p. 328. , http://dx.doi.org/10.1016/j.colsurfb.2010.03.025, PMidp20392612Scheler, S., Kitzan, M., Fahr, A., (2011) Int J. Pharm., 403, p. 207. , http://dx.doi.org/10.1016/j.ijpharm.2010.10.019, PMidp20969936Vauthier, C., Dubernet, C., Fattal, E., Pinto-Alphandary, H., Couvreur, P., (2003) Adv. Drug Deliv. Rev., 55, p. 519. , http://dx.doi.org/10.1016/S0169-409X(03)00041-3Andrieux, K., Couvreur, P., (2009) Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 1, p. 463. , http://dx.doi.org/10.1002/wnan.5, PMidp20049811Souto, E.B., (2003) Aspectos Tecnológicos da Preparação de Micro e Nanopartículas Biodegradáveis, , inp Anais do Seminário do 4° Mestrado em Tecnologia Farmacêuticas, Faculdade de Farmácia da Universidade do Porto, PortoGraf, A., McDowell, A., Rades, T., (2009) Expert Opinion on Drug Deliv., 6, p. 371. , http://dx.doi.org/10.1517/17425240902870413, PMidp19382881Soppimath, K., Kulkarni, A., Aminabhavi, T., (2001) J. Control. Release, 75, p. 331. , http://dx.doi.org/10.1016/S0168-3659(01)00404-7Arias, J.L., Ruiz, M.A., Lopez-Viota, M., Delgado, A.V., (2008) Colloids Surf B Biointerfaces, 62, p. 64. , http://dx.doi.org/10.1016/j.colsurfb.2007.09.018, PMidp17961994Bootz, A., Vogel, V., Schubert, D., Kreuter, J., (2004) Eur. J. Pharm. Biopharm., 57, p. 369. , http://dx.doi.org/10.1016/S0939-6411(03)00193-0Raynaud, J., Choquenet, B., Marie, E., Dellacherie, E., Nouvel, C., Six, J.L., Durand, A., (2008) Biomacromolecules, 8, p. 1014. , http://dx.doi.org/10.1021/bm701101n, PMidp18271550Wu, M., Dellacherie, E., Durand, A., Marie, E., (2009) Colloids Surf B Biointerfaces, 69, p. 141. , http://dx.doi.org/10.1016/j.colsurfb.2008.12.010, PMidp19147334Wu, M., Dellacherie, E., Durand, A., Marie, E., (2009) Colloids Surf B Biointerfaces, 69, p. 147. , http://dx.doi.org/10.1016/j.colsurfb.2008.10.003, PMidp19027270Alonso, M., Sanchez, A., Torres, D., Seijo, B., Vila-Jato, J., (1990) J. Microencapsul, 7, p. 517. , http://dx.doi.org/10.3109/02652049009040475, PMidp1702468Hammady, T., Rabanel, J.M., Dhanikula, R.S., Leclair, G., Hildgen, P., (2009) Eur. J. Pharm. Biopharm., 72, p. 418. , http://dx.doi.org/10.1016/j.ejpb.2009.01.007, PMidp19462478Stella, B., Arpicco, S., Rocco, F., Marsaud, V., Renoir, J.M., Cattel, L., Couvreur, P., (2007) Int J. Pharm., 344, p. 71. , http://dx.doi.org/10.1016/j.ijpharm.2007.06.006, PMidp17651931Duchene, D., Ponchel, G., Wouessidjewe, D., (1999) Adv. Drug Deliv. Rev., 36, p. 29Makhlof, A., Tozuka, Y., Takeuchi, H., (2009) Eur. J. Pharm. Biopharm., 72, p. 1. , http://dx.doi.org/10.1016/j.ejpb.2008.12.013Bernardy, N., Romio, A.P., Barcelos, E.I., Dal Pizzol, C., Dora, C.L., Lemos-Senna, E., Araujo, P.H., Sayer, C., (2010) J. Biomed. Nanotechnol., 6, p. 181. , http://dx.doi.org/10.1166/jbn.2010.1107, PMidp20738073Mora-Huertas, C.E., Fessi, H., Elaissari, A., (2010) Int J. Pharm., 385, p. 113. , http://dx.doi.org/10.1016/j.ijpharm.2009.10.018, PMidp19825408Watnasirichaikul, S., Rades, T., Tucker, I.G., Davies, N.M., (2002) Int. J. Pharm., 235, p. 237. , http://dx.doi.org/10.1016/S0378-5173(02)00002-9Gasco, M.R., Morel, S., Trotta, M., Viano, I., (1991) Pharm Acta Helv., 66, p. 47Weiss-Angeli, V., Bourgeois, S., Pelletier, J., Guterres, S.S., Fessi, H., Bolzinger, M.A., (2010) J. Pharm. Pharmacol., 62 (1), p. 35Pitaksuteepong, T., Davies, N.M., Tucker, I.G., Rades, T., (2002) Eur. J. Pharm. Biopharm., 53, p. 335. , http://dx.doi.org/10.1016/S0939-6411(01)00245-4Fontana, M.C., Coradini, K., Pohlmann, A.R., Guterres, S.S., Beck, R.C., (2010) J Nanosci. Nanotechnol., 10, p. 3091Marchiori, M.L., Lubini, G., Dalla Nora, G., Friedrich, R.B., Fontana, M.C., Ourique, A.F., Bastos, M.O., Beck, R.C., (2010) Drug Dev. Ind. Pharm., 36, p. 962. , http://dx.doi.org/10.3109/03639041003598960, PMidp20590450Khoee, S., Hossainzadeh, M.T., (2010) Colloids Surf B Biointerfaces, 75, p. 133. , http://dx.doi.org/10.1016/j.colsurfb.2009.08.021, PMidp19740631Moinard-Checot, D., Chevalier, Y., Briancon, S., Beney, L., Fessi, H., (2008) J Colloid Interface Sci., 317, p. 45